MBX Biosciences, Inc.

MBX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023
Assets
Cash & Equivalents $75.3M $49.4M $30.5M
Accounts Receivable
Inventory
Total Current Assets $381.5M $267.3M $83.5M
Property, Plant & Equipment $2.7M $1.1M $439.0K
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $385.1M $268.5M $84.2M
Liabilities
Accounts Payable $3.0M $5.3M $1.4M
Total Current Liabilities $15.5M $11.1M $3.9M
Long-Term Debt
Total Liabilities $15.9M $11.1M $4.3M
Stockholders' Equity
Retained Earnings $-224.5M $-137.5M $-75.6M
Total Stockholders' Equity $369.2M $257.4M $-72.5M